Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. - Wikidata - wikimedia - TriplyDB

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.

http://www.wikidata.org/entity/Q33389767

about

Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Cytokine-Induced Modulation of Colorectal Cancer Tremelimumab: research and clinical development Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis The past, present and future of immunotherapy against tumor Immunotherapy advances for glioblastoma The emerging role of immunotherapy in colorectal cancer Immunotherapy in human colorectal cancer: Challenges and prospective Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma.Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress Immunotherapy for metastatic solid cancers Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies Antibody-based therapeutics to watch in 2011.Clinical Development of Immune Checkpoint Inhibitors.Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives.Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer.Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".Systematic evaluation of immune regulation and modulation Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death Regulatory T cells in gastrointestinal tumors.Targeting costimulatory molecules to improve antitumor immunity.Tremelimumab: a review of development to date in solid tumors.Antibody-based therapy in colorectal cancer.Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.Checkpoint blocking antibodies in cancer immunotherapy.Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?Impact of the immune system and immunotherapy in colorectal cancer.Tremelimumab for the treatment of malignant mesothelioma.

P2860

Q26751344-B6A41766-D583-48E0-BCC5-DC4FC896BC2B Q26752374-FDF11231-9E43-4503-A4A0-F98471C23FE1 Q26752822-28CD5DAA-D3DB-4AC9-8693-B05510076807 Q26775578-9C5491C6-FBF1-4B34-A681-E7C9923C413B Q26785746-AE79BC43-511D-438A-93C5-A6E6EF7A8DC1 Q26799896-F0D94B5C-CAB1-48F3-8CEA-F49D9CAC91EB Q26866513-EFC3B070-6520-4D21-B694-E60156ED725C Q28067898-1ACE3887-C578-4B44-8138-E6BBF2376CE4 Q28068788-3A362592-2682-48D6-A5DC-C30981027E39 Q28076970-44CEE73E-6E75-42DC-8185-6D61CBACACFC Q28083810-4FEBED63-1589-4BEE-AE33-5772143FC632 Q30235360-4AB19B73-3E35-4FEF-98A7-7AAA3EB91310 Q30317446-6EEF7AC5-327D-4238-96F1-7C72E06891DC Q33396455-BD264512-1C65-47F5-81D3-8763A382FBC7 Q33593871-72C4326C-94D9-4A76-A0E0-2C49860ED336 Q34219970-11F51B7A-408C-416D-9B82-D74033872010 Q34511672-A33C20FF-CE8A-4FA5-A358-6542A565582E Q34570079-0C31845A-550B-4D69-8C1F-AEDDC47C38A0 Q34671498-66AF0E5B-2A16-4964-AF09-AB0CAEE0F6DE Q35664913-97F3E206-184E-4964-A68F-FC2D875CF691 Q35913194-27FCC2CA-D87E-4E40-9AE3-B8A845157AEF Q35951653-9B23B550-886E-4F6B-900B-B736440A7742 Q36114649-E99744D9-8807-4A96-B084-4D225E542DE3 Q36711013-73F9A1D4-B831-40DF-927F-637F6C1CB2F0 Q37091138-4A653FED-8F84-4103-BFE8-41D8CCCE077F Q37125759-447D2E47-0F8A-4DC0-BB01-B5F77C3A09C5 Q37137360-E0DE4ED4-59A9-41BD-ABDF-D62707E007BC Q37590119-7843643D-9661-4AAE-A30C-58624F27AF8C Q37670024-15D7DF32-D902-445A-A425-7F147292FBBD Q37713498-395B1797-8D07-481E-8411-B24058C1A3F0 Q37745133-14B95446-DCDE-493D-A3CB-F0F4F07E21B7 Q37903852-8CB8BDA4-B75D-47CE-9286-65FE8446A076 Q38002404-4CEB9AAF-00FE-49FD-8D1E-9D649165B3B5 Q38085028-9EC9CDAC-606E-471E-8009-766CEFC980DF Q38103583-87C7DCEE-9C5A-4167-8898-F01BEDB4645B Q38154151-2C00B924-0ED8-4588-8DF8-A61D7CD7B40D Q38155703-55EBA413-D588-46FE-9DAE-9CC2DD0F7FF0 Q38372284-CE0AEEDA-F45E-4332-AEBB-B010A8C24631 Q38398877-0FAF11E4-4D60-41BD-8879-300ACE4C8D65 Q38631254-1E9DC9B8-AD14-44F1-8122-2A391536C2F7

P2860

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.

http://www.wikidata.org/entity/Q33389767

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase II study of the anti-cyt ...... metastatic colorectal cancer.

@ast

Phase II study of the anti-cyt ...... metastatic colorectal cancer.

@en

type

label

Phase II study of the anti-cyt ...... metastatic colorectal cancer.

@ast

Phase II study of the anti-cyt ...... metastatic colorectal cancer.

@en

prefLabel

Phase II study of the anti-cyt ...... metastatic colorectal cancer.

@ast

Phase II study of the anti-cyt ...... metastatic colorectal cancer.

@en

P1433

Q33389767-B79A835B-0BD4-4209-AE5D-9D7B7C3EC89D

P1476

Q33389767-E12369C9-65A6-47A4-8B00-6DBC264380D2

P2093

Q33389767-097A972B-B69A-48F0-9A6B-F75536670D4C

Q33389767-2A07632A-D88C-4C92-85B9-3686D4624BC9

Q33389767-2E14EF44-B305-41AA-B56A-8A0C488C3EBC

Q33389767-38A04C10-860D-44A7-BFE2-E68FAFECC714

Q33389767-3CCC8B76-A92C-455F-8B39-9964B662A2D1

Q33389767-4F387B24-CE1B-481C-BD4C-8B73E6370656

Q33389767-732D4838-5483-471E-9ED5-22CB354F413F

Q33389767-77717DF9-01C6-4540-91D1-5AF155F06EA6

Q33389767-7C754FD1-CD6B-483F-B812-889C3E281DA9

Q33389767-DA2EB924-28DB-451F-8D94-9CA8F067CBF6

P304

Q33389767-8DC1EEC8-AAD5-4DFC-AA0C-97FA8E68548D

P31

Q33389767-5074FDA4-FE0C-413F-9CEC-9753A53ACAAA

P356

Q33389767-D4AD3F8B-0A0B-48F6-BBCE-EEE56E252770

P407

Q33389767-035AA56C-CB6D-4376-BEEC-7FF6D7467065

P433

Q33389767-AD88BB36-61FC-4DE1-BABB-24E60FC2A7B8

P478

Q33389767-22DA0365-91E4-497A-AE34-D8497B108E1D

P50

Q33389767-72A74925-22D1-40B3-B44A-13D68AE0EF58

P577

Q33389767-256098E4-8AB5-47A3-B491-8CCA150147A4

P698

Q33389767-7BA7D97D-3392-42D5-B796-A76C4E913E48

P921

Q33389767-24C73693-A5ED-42ED-80E8-3EFF70F2DCE8

Q33389767-68C2DFC2-E7B1-4270-8645-D4701DC135F3

Q33389767-A2FD00E1-D67F-464D-B390-6A69FE26F3D4

Q33389767-F0180397-4D43-4356-BB0C-0985998DDF47

P356

JCO.2010.28.3994

P1433

Journal of Clinical Oncology

P1476

Phase II study of the anti-cyt ...... metastatic colorectal cancer.

@en

P2093

Alan Venook

http://www.w3.org/2001/XMLSchema#string

Bo Huang

http://www.w3.org/2001/XMLSchema#string

Diane I Healey

http://www.w3.org/2001/XMLSchema#string

Ira Gore

http://www.w3.org/2001/XMLSchema#string

Jesus Gomez-Navarro

http://www.w3.org/2001/XMLSchema#string

Ki Y Chung

http://www.w3.org/2001/XMLSchema#string

Lawrence Fong

http://www.w3.org/2001/XMLSchema#string

Peggy J Criscitiello

http://www.w3.org/2001/XMLSchema#string

Prudence Dorazio

http://www.w3.org/2001/XMLSchema#string

Stephen B Beck

http://www.w3.org/2001/XMLSchema#string

P304

3485-3490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.28.3994

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Leonard B. Saltz

P577

2010-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20498386

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer